Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01827540 · ClinicalTrials.gov registry record · Phase 1
Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
A Phase 1 study, sponsored by Tobira Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01827540 is a Phase 1 study that has completed, run by Tobira Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT01827540, a Phase 1 study, has completed, sponsored by Tobira Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
To evaluate the PK, safety and tolerability of Cenicriviroc (CVC) administered with and without Dolutegravir (DTG) and CVC with and without a single dose of Midazolam in healthy subjects.
Interventions
- DRUG Midazolam
- DRUG Dolutegravir
- DRUG Cenicriviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01827540
The ClinicalTrials.gov registry entry for NCT01827540 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tobira Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam is the first listed.
NCT01827540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01827540 about?
NCT01827540 is a clinical study titled "Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam". To evaluate the PK, safety and tolerability of Cenicriviroc (CVC) administered with and without Dolutegravir (DTG) and CVC with and without a single dose of Midazolam in healthy subjects.
What is the current status of trial NCT01827540?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-03. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01827540?
The interventions under investigation include: Midazolam (DRUG), Dolutegravir (DRUG), Cenicriviroc (DRUG).
Who is sponsoring clinical trial NCT01827540?
This trial is sponsored by Tobira Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.